In vivo CYP2E1 phenotyping as a new potential biomarker of occupational and experimental exposure to benzene

Assessing CYP2E1 phenotype in vivo may be important to predict individual susceptibility to those chemicals, including benzene, which are metabolically activated by this isoenzyme. Chlorzoxazone (CHZ), a specific CYP2E1 substrate, is readily hydroxylated to 6-OH-chlorzoxazone (6-OH-CHZ) by liver CYP...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Toxicology letters 2010-01, Vol.192 (1), p.29-33
Hauptverfasser: Piccoli, P., Carrieri, M., Padovano, L., Di Mare, M., Bartolucci, G.B., Fracasso, M.E., Lepera, J.S., Manno, M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 33
container_issue 1
container_start_page 29
container_title Toxicology letters
container_volume 192
creator Piccoli, P.
Carrieri, M.
Padovano, L.
Di Mare, M.
Bartolucci, G.B.
Fracasso, M.E.
Lepera, J.S.
Manno, M.
description Assessing CYP2E1 phenotype in vivo may be important to predict individual susceptibility to those chemicals, including benzene, which are metabolically activated by this isoenzyme. Chlorzoxazone (CHZ), a specific CYP2E1 substrate, is readily hydroxylated to 6-OH-chlorzoxazone (6-OH-CHZ) by liver CYP2E1 and the metabolic ratio 6-OH-CHZ/CHZ in serum (MR) is a specific and sensitive biomarker of CYP2E1 activity in vivo in humans. We used this MR as a potential biomarker of effect in benzene-treated rats and, also, in humans occupationally exposed to low levels of benzene. Male Sprague-Dawley rats (375–400 g b.w.) were treated i.p. for 3 days with either a 0.5 ml solution of benzene (5 mmol/kg b.w.) in corn oil, or 0.5 ml corn oil alone. Twenty-four hours after the last injection, a polyethylene glycol (PEG) solution of CHZ (20 mg/kg b.w.) was injected i.p. in both treated and control animals. After 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, and 240 min from injection, 0.2 ml blood was taken from the tip tail and stored at −20 °C until analysis. A modified reverse phase HPLC method using a 5 μm Ultrasphere C18 column equipped with a direct-connection ODS guard column, was used to measure CHZ and its metabolite 6-OH-CHZ in serum. No statistically significant difference in the MR was observed, at any sampling time, between benzene-treated and control rats. The concentration-versus-time area under the curve (AUC), however, was lower ( p < 0.05, Mann–Whitney test), whereas the systemic clearance was higher ( p < 0.05) in treated than in control rats. Eleven petrochemical workers occupationally exposed to low levels of airborne benzene (mean ± SD, 25.0 ± 24.4 μg/m 3) and 13 non-exposed controls from the same factory (mean ± SD, 6.7 ± 4.0 μg/m 3) signed an informed consent form and were administered 500 mg CHZ p.o. Two hours later a venous blood sample was taken for CHZ and 6-OH-CHZ measurements. Despite exposed subjects showed significantly higher levels of t,t-MA and S-PMA, two biomarkers of exposure to benzene, than non-exposed workers, no difference in the MR mean values ± SD was found between exposed (0.59 ± 0.29) and non-exposed (0.57 ± 0.23) subjects. So, benzene was found to modify CHZ disposition, but not CYP2E1 phenotype in benzene-treated rats, nor in workers exposed to benzene, probably due to the levels of exposure being too low.
doi_str_mv 10.1016/j.toxlet.2009.10.023
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_744613006</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378427409014787</els_id><sourcerecordid>733618167</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-248db3e0822132ac335507fccce697fe1a07ba5757afa54408c10970e04557ec3</originalsourceid><addsrcrecordid>eNqFkU9v1DAQxSMEotvCN0DIFwSXLOP4X3JBqlalVKoEBzhwshzvBLxk7WA7S8unx9Gu4FZOo3n-zYz1XlW9oLCmQOXb3TqHuxHzugHoirSGhj2qVrRVXc2o7B5XK2CqrXmj-Fl1ntIOACSX4ml1RrsOQFC-qsYbTw7uEMjm66fmipLpO_qQ7yfnvxGTiCEef5EpZPTZmZH0LuxN_IGRhIEEa-fJZBd8eTF-S_Buwuj2hS1CaUKaI5IcSI_-N3p8Vj0ZzJjw-aleVF_eX33efKhvP17fbC5va8uFzHXD223PENqmoawxljEhQA3WWpSdGpAaUL0RSigzGME5tJZCpwCBC6HQsovq9XHvFMPPGVPWe5csjqPxGOakFeeSsuLG_0nGJG2pVIV88yBZGMpBglqW8iNqY0gp4qCn4oqJ95qCXrLTO33MTi_ZLWrJroy9PF2Y-z1u_w2dwirAqxNgkjXjEI23Lv3lmqY40YmFe3fksHh8cBh1sg69xa2LaLPeBvfwT_4AwPq5Fg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1671406076</pqid></control><display><type>article</type><title>In vivo CYP2E1 phenotyping as a new potential biomarker of occupational and experimental exposure to benzene</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Piccoli, P. ; Carrieri, M. ; Padovano, L. ; Di Mare, M. ; Bartolucci, G.B. ; Fracasso, M.E. ; Lepera, J.S. ; Manno, M.</creator><creatorcontrib>Piccoli, P. ; Carrieri, M. ; Padovano, L. ; Di Mare, M. ; Bartolucci, G.B. ; Fracasso, M.E. ; Lepera, J.S. ; Manno, M.</creatorcontrib><description>Assessing CYP2E1 phenotype in vivo may be important to predict individual susceptibility to those chemicals, including benzene, which are metabolically activated by this isoenzyme. Chlorzoxazone (CHZ), a specific CYP2E1 substrate, is readily hydroxylated to 6-OH-chlorzoxazone (6-OH-CHZ) by liver CYP2E1 and the metabolic ratio 6-OH-CHZ/CHZ in serum (MR) is a specific and sensitive biomarker of CYP2E1 activity in vivo in humans. We used this MR as a potential biomarker of effect in benzene-treated rats and, also, in humans occupationally exposed to low levels of benzene. Male Sprague-Dawley rats (375–400 g b.w.) were treated i.p. for 3 days with either a 0.5 ml solution of benzene (5 mmol/kg b.w.) in corn oil, or 0.5 ml corn oil alone. Twenty-four hours after the last injection, a polyethylene glycol (PEG) solution of CHZ (20 mg/kg b.w.) was injected i.p. in both treated and control animals. After 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, and 240 min from injection, 0.2 ml blood was taken from the tip tail and stored at −20 °C until analysis. A modified reverse phase HPLC method using a 5 μm Ultrasphere C18 column equipped with a direct-connection ODS guard column, was used to measure CHZ and its metabolite 6-OH-CHZ in serum. No statistically significant difference in the MR was observed, at any sampling time, between benzene-treated and control rats. The concentration-versus-time area under the curve (AUC), however, was lower ( p &lt; 0.05, Mann–Whitney test), whereas the systemic clearance was higher ( p &lt; 0.05) in treated than in control rats. Eleven petrochemical workers occupationally exposed to low levels of airborne benzene (mean ± SD, 25.0 ± 24.4 μg/m 3) and 13 non-exposed controls from the same factory (mean ± SD, 6.7 ± 4.0 μg/m 3) signed an informed consent form and were administered 500 mg CHZ p.o. Two hours later a venous blood sample was taken for CHZ and 6-OH-CHZ measurements. Despite exposed subjects showed significantly higher levels of t,t-MA and S-PMA, two biomarkers of exposure to benzene, than non-exposed workers, no difference in the MR mean values ± SD was found between exposed (0.59 ± 0.29) and non-exposed (0.57 ± 0.23) subjects. So, benzene was found to modify CHZ disposition, but not CYP2E1 phenotype in benzene-treated rats, nor in workers exposed to benzene, probably due to the levels of exposure being too low.</description><identifier>ISSN: 0378-4274</identifier><identifier>EISSN: 1879-3169</identifier><identifier>DOI: 10.1016/j.toxlet.2009.10.023</identifier><identifier>PMID: 19900514</identifier><identifier>CODEN: TOLED5</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>6-OH-chlorzoxazone ; Acetylcysteine - analogs &amp; derivatives ; Acetylcysteine - urine ; Animals ; Area Under Curve ; Benzene ; Benzene - pharmacokinetics ; Benzene - toxicity ; Biocompatibility ; Biological and medical sciences ; Biomarkers - blood ; Biomarkers - metabolism ; Biomedical materials ; Chlorzoxazone ; Chlorzoxazone - analogs &amp; derivatives ; Chlorzoxazone - blood ; Chlorzoxazone - pharmacokinetics ; Chromatography, High Pressure Liquid ; CYP2E1 ; Cytochrome P-450 CYP2E1 - metabolism ; Exposure ; Humans ; In vivo testing ; In vivo tests ; Male ; Medical sciences ; Metabolic phenotype ; Occupational Exposure - analysis ; Phenotype ; Random Allocation ; Rats ; Rats, Sprague-Dawley ; Sorbic Acid - analogs &amp; derivatives ; Sorbic Acid - analysis ; Statistics, Nonparametric ; Surgical implants ; Toxicology</subject><ispartof>Toxicology letters, 2010-01, Vol.192 (1), p.29-33</ispartof><rights>2009 Elsevier Ireland Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright 2009 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-248db3e0822132ac335507fccce697fe1a07ba5757afa54408c10970e04557ec3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0378427409014787$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,776,780,785,786,3537,23909,23910,25118,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=22408954$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19900514$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Piccoli, P.</creatorcontrib><creatorcontrib>Carrieri, M.</creatorcontrib><creatorcontrib>Padovano, L.</creatorcontrib><creatorcontrib>Di Mare, M.</creatorcontrib><creatorcontrib>Bartolucci, G.B.</creatorcontrib><creatorcontrib>Fracasso, M.E.</creatorcontrib><creatorcontrib>Lepera, J.S.</creatorcontrib><creatorcontrib>Manno, M.</creatorcontrib><title>In vivo CYP2E1 phenotyping as a new potential biomarker of occupational and experimental exposure to benzene</title><title>Toxicology letters</title><addtitle>Toxicol Lett</addtitle><description>Assessing CYP2E1 phenotype in vivo may be important to predict individual susceptibility to those chemicals, including benzene, which are metabolically activated by this isoenzyme. Chlorzoxazone (CHZ), a specific CYP2E1 substrate, is readily hydroxylated to 6-OH-chlorzoxazone (6-OH-CHZ) by liver CYP2E1 and the metabolic ratio 6-OH-CHZ/CHZ in serum (MR) is a specific and sensitive biomarker of CYP2E1 activity in vivo in humans. We used this MR as a potential biomarker of effect in benzene-treated rats and, also, in humans occupationally exposed to low levels of benzene. Male Sprague-Dawley rats (375–400 g b.w.) were treated i.p. for 3 days with either a 0.5 ml solution of benzene (5 mmol/kg b.w.) in corn oil, or 0.5 ml corn oil alone. Twenty-four hours after the last injection, a polyethylene glycol (PEG) solution of CHZ (20 mg/kg b.w.) was injected i.p. in both treated and control animals. After 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, and 240 min from injection, 0.2 ml blood was taken from the tip tail and stored at −20 °C until analysis. A modified reverse phase HPLC method using a 5 μm Ultrasphere C18 column equipped with a direct-connection ODS guard column, was used to measure CHZ and its metabolite 6-OH-CHZ in serum. No statistically significant difference in the MR was observed, at any sampling time, between benzene-treated and control rats. The concentration-versus-time area under the curve (AUC), however, was lower ( p &lt; 0.05, Mann–Whitney test), whereas the systemic clearance was higher ( p &lt; 0.05) in treated than in control rats. Eleven petrochemical workers occupationally exposed to low levels of airborne benzene (mean ± SD, 25.0 ± 24.4 μg/m 3) and 13 non-exposed controls from the same factory (mean ± SD, 6.7 ± 4.0 μg/m 3) signed an informed consent form and were administered 500 mg CHZ p.o. Two hours later a venous blood sample was taken for CHZ and 6-OH-CHZ measurements. Despite exposed subjects showed significantly higher levels of t,t-MA and S-PMA, two biomarkers of exposure to benzene, than non-exposed workers, no difference in the MR mean values ± SD was found between exposed (0.59 ± 0.29) and non-exposed (0.57 ± 0.23) subjects. So, benzene was found to modify CHZ disposition, but not CYP2E1 phenotype in benzene-treated rats, nor in workers exposed to benzene, probably due to the levels of exposure being too low.</description><subject>6-OH-chlorzoxazone</subject><subject>Acetylcysteine - analogs &amp; derivatives</subject><subject>Acetylcysteine - urine</subject><subject>Animals</subject><subject>Area Under Curve</subject><subject>Benzene</subject><subject>Benzene - pharmacokinetics</subject><subject>Benzene - toxicity</subject><subject>Biocompatibility</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Biomarkers - metabolism</subject><subject>Biomedical materials</subject><subject>Chlorzoxazone</subject><subject>Chlorzoxazone - analogs &amp; derivatives</subject><subject>Chlorzoxazone - blood</subject><subject>Chlorzoxazone - pharmacokinetics</subject><subject>Chromatography, High Pressure Liquid</subject><subject>CYP2E1</subject><subject>Cytochrome P-450 CYP2E1 - metabolism</subject><subject>Exposure</subject><subject>Humans</subject><subject>In vivo testing</subject><subject>In vivo tests</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic phenotype</subject><subject>Occupational Exposure - analysis</subject><subject>Phenotype</subject><subject>Random Allocation</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Sorbic Acid - analogs &amp; derivatives</subject><subject>Sorbic Acid - analysis</subject><subject>Statistics, Nonparametric</subject><subject>Surgical implants</subject><subject>Toxicology</subject><issn>0378-4274</issn><issn>1879-3169</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9v1DAQxSMEotvCN0DIFwSXLOP4X3JBqlalVKoEBzhwshzvBLxk7WA7S8unx9Gu4FZOo3n-zYz1XlW9oLCmQOXb3TqHuxHzugHoirSGhj2qVrRVXc2o7B5XK2CqrXmj-Fl1ntIOACSX4ml1RrsOQFC-qsYbTw7uEMjm66fmipLpO_qQ7yfnvxGTiCEef5EpZPTZmZH0LuxN_IGRhIEEa-fJZBd8eTF-S_Buwuj2hS1CaUKaI5IcSI_-N3p8Vj0ZzJjw-aleVF_eX33efKhvP17fbC5va8uFzHXD223PENqmoawxljEhQA3WWpSdGpAaUL0RSigzGME5tJZCpwCBC6HQsovq9XHvFMPPGVPWe5csjqPxGOakFeeSsuLG_0nGJG2pVIV88yBZGMpBglqW8iNqY0gp4qCn4oqJ95qCXrLTO33MTi_ZLWrJroy9PF2Y-z1u_w2dwirAqxNgkjXjEI23Lv3lmqY40YmFe3fksHh8cBh1sg69xa2LaLPeBvfwT_4AwPq5Fg</recordid><startdate>20100115</startdate><enddate>20100115</enddate><creator>Piccoli, P.</creator><creator>Carrieri, M.</creator><creator>Padovano, L.</creator><creator>Di Mare, M.</creator><creator>Bartolucci, G.B.</creator><creator>Fracasso, M.E.</creator><creator>Lepera, J.S.</creator><creator>Manno, M.</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FD</scope><scope>FR3</scope><scope>KR7</scope><scope>7X8</scope><scope>7ST</scope><scope>7T2</scope><scope>7U2</scope><scope>7U7</scope><scope>C1K</scope><scope>SOI</scope></search><sort><creationdate>20100115</creationdate><title>In vivo CYP2E1 phenotyping as a new potential biomarker of occupational and experimental exposure to benzene</title><author>Piccoli, P. ; Carrieri, M. ; Padovano, L. ; Di Mare, M. ; Bartolucci, G.B. ; Fracasso, M.E. ; Lepera, J.S. ; Manno, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-248db3e0822132ac335507fccce697fe1a07ba5757afa54408c10970e04557ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>6-OH-chlorzoxazone</topic><topic>Acetylcysteine - analogs &amp; derivatives</topic><topic>Acetylcysteine - urine</topic><topic>Animals</topic><topic>Area Under Curve</topic><topic>Benzene</topic><topic>Benzene - pharmacokinetics</topic><topic>Benzene - toxicity</topic><topic>Biocompatibility</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Biomarkers - metabolism</topic><topic>Biomedical materials</topic><topic>Chlorzoxazone</topic><topic>Chlorzoxazone - analogs &amp; derivatives</topic><topic>Chlorzoxazone - blood</topic><topic>Chlorzoxazone - pharmacokinetics</topic><topic>Chromatography, High Pressure Liquid</topic><topic>CYP2E1</topic><topic>Cytochrome P-450 CYP2E1 - metabolism</topic><topic>Exposure</topic><topic>Humans</topic><topic>In vivo testing</topic><topic>In vivo tests</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic phenotype</topic><topic>Occupational Exposure - analysis</topic><topic>Phenotype</topic><topic>Random Allocation</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Sorbic Acid - analogs &amp; derivatives</topic><topic>Sorbic Acid - analysis</topic><topic>Statistics, Nonparametric</topic><topic>Surgical implants</topic><topic>Toxicology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Piccoli, P.</creatorcontrib><creatorcontrib>Carrieri, M.</creatorcontrib><creatorcontrib>Padovano, L.</creatorcontrib><creatorcontrib>Di Mare, M.</creatorcontrib><creatorcontrib>Bartolucci, G.B.</creatorcontrib><creatorcontrib>Fracasso, M.E.</creatorcontrib><creatorcontrib>Lepera, J.S.</creatorcontrib><creatorcontrib>Manno, M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Civil Engineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Environment Abstracts</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Environment Abstracts</collection><jtitle>Toxicology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Piccoli, P.</au><au>Carrieri, M.</au><au>Padovano, L.</au><au>Di Mare, M.</au><au>Bartolucci, G.B.</au><au>Fracasso, M.E.</au><au>Lepera, J.S.</au><au>Manno, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vivo CYP2E1 phenotyping as a new potential biomarker of occupational and experimental exposure to benzene</atitle><jtitle>Toxicology letters</jtitle><addtitle>Toxicol Lett</addtitle><date>2010-01-15</date><risdate>2010</risdate><volume>192</volume><issue>1</issue><spage>29</spage><epage>33</epage><pages>29-33</pages><issn>0378-4274</issn><eissn>1879-3169</eissn><coden>TOLED5</coden><abstract>Assessing CYP2E1 phenotype in vivo may be important to predict individual susceptibility to those chemicals, including benzene, which are metabolically activated by this isoenzyme. Chlorzoxazone (CHZ), a specific CYP2E1 substrate, is readily hydroxylated to 6-OH-chlorzoxazone (6-OH-CHZ) by liver CYP2E1 and the metabolic ratio 6-OH-CHZ/CHZ in serum (MR) is a specific and sensitive biomarker of CYP2E1 activity in vivo in humans. We used this MR as a potential biomarker of effect in benzene-treated rats and, also, in humans occupationally exposed to low levels of benzene. Male Sprague-Dawley rats (375–400 g b.w.) were treated i.p. for 3 days with either a 0.5 ml solution of benzene (5 mmol/kg b.w.) in corn oil, or 0.5 ml corn oil alone. Twenty-four hours after the last injection, a polyethylene glycol (PEG) solution of CHZ (20 mg/kg b.w.) was injected i.p. in both treated and control animals. After 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, and 240 min from injection, 0.2 ml blood was taken from the tip tail and stored at −20 °C until analysis. A modified reverse phase HPLC method using a 5 μm Ultrasphere C18 column equipped with a direct-connection ODS guard column, was used to measure CHZ and its metabolite 6-OH-CHZ in serum. No statistically significant difference in the MR was observed, at any sampling time, between benzene-treated and control rats. The concentration-versus-time area under the curve (AUC), however, was lower ( p &lt; 0.05, Mann–Whitney test), whereas the systemic clearance was higher ( p &lt; 0.05) in treated than in control rats. Eleven petrochemical workers occupationally exposed to low levels of airborne benzene (mean ± SD, 25.0 ± 24.4 μg/m 3) and 13 non-exposed controls from the same factory (mean ± SD, 6.7 ± 4.0 μg/m 3) signed an informed consent form and were administered 500 mg CHZ p.o. Two hours later a venous blood sample was taken for CHZ and 6-OH-CHZ measurements. Despite exposed subjects showed significantly higher levels of t,t-MA and S-PMA, two biomarkers of exposure to benzene, than non-exposed workers, no difference in the MR mean values ± SD was found between exposed (0.59 ± 0.29) and non-exposed (0.57 ± 0.23) subjects. So, benzene was found to modify CHZ disposition, but not CYP2E1 phenotype in benzene-treated rats, nor in workers exposed to benzene, probably due to the levels of exposure being too low.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>19900514</pmid><doi>10.1016/j.toxlet.2009.10.023</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0378-4274
ispartof Toxicology letters, 2010-01, Vol.192 (1), p.29-33
issn 0378-4274
1879-3169
language eng
recordid cdi_proquest_miscellaneous_744613006
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects 6-OH-chlorzoxazone
Acetylcysteine - analogs & derivatives
Acetylcysteine - urine
Animals
Area Under Curve
Benzene
Benzene - pharmacokinetics
Benzene - toxicity
Biocompatibility
Biological and medical sciences
Biomarkers - blood
Biomarkers - metabolism
Biomedical materials
Chlorzoxazone
Chlorzoxazone - analogs & derivatives
Chlorzoxazone - blood
Chlorzoxazone - pharmacokinetics
Chromatography, High Pressure Liquid
CYP2E1
Cytochrome P-450 CYP2E1 - metabolism
Exposure
Humans
In vivo testing
In vivo tests
Male
Medical sciences
Metabolic phenotype
Occupational Exposure - analysis
Phenotype
Random Allocation
Rats
Rats, Sprague-Dawley
Sorbic Acid - analogs & derivatives
Sorbic Acid - analysis
Statistics, Nonparametric
Surgical implants
Toxicology
title In vivo CYP2E1 phenotyping as a new potential biomarker of occupational and experimental exposure to benzene
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T12%3A00%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vivo%20CYP2E1%20phenotyping%20as%20a%20new%20potential%20biomarker%20of%20occupational%20and%20experimental%20exposure%20to%20benzene&rft.jtitle=Toxicology%20letters&rft.au=Piccoli,%20P.&rft.date=2010-01-15&rft.volume=192&rft.issue=1&rft.spage=29&rft.epage=33&rft.pages=29-33&rft.issn=0378-4274&rft.eissn=1879-3169&rft.coden=TOLED5&rft_id=info:doi/10.1016/j.toxlet.2009.10.023&rft_dat=%3Cproquest_cross%3E733618167%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1671406076&rft_id=info:pmid/19900514&rft_els_id=S0378427409014787&rfr_iscdi=true